Carboplatin Articles
Isis/Lilly's Affinitak disappoints in Ph III
24 March 2003
Oncosense licenses ruthenium-based cancer drugs
27 January 2003
Gensia Sicor's generic carboplatin gets initial OK
19 August 2002
OXiGENE advances CA4P into Phase Ib
10 June 2002
Herceptin disappoints in lung cancer
3 June 2002
Taxol vs Taxotere trial finds tox advantage
3 June 2002
New data on Ligand's Targretin, Ontak
27 May 2002
Alimta: first effective mesothelioma drug
27 May 2002
Lilly starts pivotal trial of antisense NSCLC drug
29 April 2002
InterMune starts Ph III ovarian cancer trial
11 February 2002
Isis says Phase III trial complete for LY900003.
21 January 2002
ISIS 3521 news
8 November 2001
Genentech boosted by Avastin study
26 October 2001
Ribozyme begins third Angiozyme trial
26 September 2001
Trials begin for Protarga's cancer drug
8 June 2001
Xenova reports positive Ph II data for XR9576
15 May 2001
IM862 potential in combined cancer therapy?
8 May 2001
Euro NSCLC market sees renewed growth
21 March 2001
Bristol-Myers Squibb's "solid year" sees net earnings rise 13%
25 January 2001
Fast-track review for Isis
15 November 2000
No surprise as British Biotech fails again
27 September 2000
AstraZeneca launches Losec follow-up Nexium in the UK
12 September 2000
NEJM warns against breast cancer therapy
8 March 2000
Genentech begins pivotal trial of RhuMAb-VEGF
4 January 2000
Genentech boosted on asthma data, BLA 2000
21 December 1999
Swiss major Novartis Pharma pulls out of Isis cancer drug deal
23 November 1999
Exisulind plus docetaxel to target multiple tumor types
30 September 1999
B-MS, Otsuka link up on new antipsychotic
22 September 1999
Magainin's Locilex "not approvable"
27 July 1999
Squalamine enters Phase II for NSCLC
25 June 1999
Alkermes stops Cereport trial
8 April 1999
US NCI trial Celgene's Thalomid in NSCL cancer
29 March 1999
Sanofi's Eloxatin Gearing Up For Global Roll-Out
30 June 1998
Cancer Market Growth Forecasts To 2010
15 June 1998
Expanded Use Of R-PR's Taxotere Backed
4 June 1998
Taxol, Platinum "Optimal" For Ovarian Cancer
27 May 1998
Agouron Starts Pivotal Trials Of AG3340
7 May 1998
Zeneca Licenses AnorMED Anticancer
15 April 1998
News From The AACR Meeting In Brief
2 April 1998
British Biotech Starts Ovarian Cancer Trial
2 October 1997
BioNumerik Begins Trials With BNP7787
17 September 1997
Preliminary Data With Alkermes' RMP-7
11 September 1997
British Biotech Pipeline Close To Bearing First Fruit
17 March 1997
Amgen's Promising MGDF For Thrombocytopenia
17 February 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Alkermes Reports On Ph II Data With RMP-7
6 January 1997
British Biotech Share Price Falls After Marimastat Data
11 November 1996
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
NCI Study Of Alkermes' RMP-7
12 August 1996
SB's Hycamtin Backed By US Committee
29 April 1996
Alkermes Expands RMP-7 Testing
29 April 1996
Alkermes' RMP-7
8 April 1996
Mixed Results For Q4 1995 From US Drug Majors
29 January 1996
Taxol Improves Survival In Ovarian Cancer Patients
15 January 1996
Sandoz MDR Drug Shows Promise In Early Trials
13 November 1995
Alkermes Begins Phase II trials
17 April 1995
Alkermes Starts RMP-7 Efficacy Trials
20 February 1995
Alkermes Updates On RMP-7 Progress
16 January 1995
Lilly's Gemcitabine; First Phase III Results
28 November 1994
Overcoming The Blood-Brain Barrier
18 July 1994
ALKERMES' RMP-7 BREAKS THE BRAIN BARRIER
11 July 1994
US BIO'S HEXALEN IN OVARIAN CANCER
11 April 1994
B-MS LAUNCHES TAXOL IN UK
17 January 1994
TAXOL REVEALS FURTHER POTENTIAL
25 October 1993
EC'S CPMP BACKS TAXOL APPROVAL
27 September 1993
CANCER MEDICINES IN DEVELOPMENT
14 June 1993
CLINICAL PROGRESS WITH TOPO I INHIBITORS
31 May 1993
WORLD ANTICANCER/ IMMUNOLOGY MARKET
8 February 1993
NEW CANCER DRUGS SHINE AT US MEETING
2 November 1992
STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB
20 April 1992
AIDS TREATMENT FROM JOHNSON MATTHEY
17 February 1992
EC PLENARY SESSION DECISIONS
6 January 1992
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
